SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Cellular Biomedicine Group Inc.
NEW YORK, April 7, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Cellular Biomedicine Group Inc. ("Cellular Biomedicine Group" or the "Company") (NasdaqCM: CBMG -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at [email protected] or 212-697-6484.
The investigation concerns whether Cellular Biomedicine Group and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On April 7, 2015, Seeking Alpha published a report on Cellular Biomedicine Group, which asserts that: (i) it has achieved an unsustainable valuation with paid stock promotion; (ii) its "CAR-T" technology has experienced patient deaths and is worthless; (iii) its founders face multiple allegations of dishonesty and are responsible for an alleged illegal offshore stem cell clinic; and (iv) it has multiple accounting and financial integrity issues. On this news, shares of Cellular Biomedicine Group fell sharply during intraday trading on April 7, 2015.
Following this news, shares of Cellular Biomedicine Group fell $7.40, or 22.95%, during intraday trading to trade at $24.83.76 on April 7, 2015
If you are aware of any facts relating to this investigation, or purchased shares of Cellular Biomedicine Group , you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
[email protected]
SOURCE Bronstein, Gewirtz & Grossman, LLC
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article